Drug profile · INN
nitisinone
NITYR
nitisinone (NITYR) is a 4-hydroxyphenylpyruvate dioxygenase inhibitor. Associated with Eton Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
Drug details — nitisinone
- US status
- approved
- Class
- Alimentary tract and metabolism (A16)
- Route
- ORAL
- Patents
- 20
- Programs
- 0
- Data quality
- 0.89
Quick answer
nitisinone (NITYR) is a 4-hydroxyphenylpyruvate dioxygenase inhibitor. Associated with Eton Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
4-hydroxyphenylpyruvate dioxygenase inhibitor
Primary target: 4-hydroxyphenylpyruvate dioxygenase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Related & competitor drugs
Related patents
-
US 12186436
Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
granted -
US 12083230
Nano-encapsulation using GRAS materials and applications thereof
granted -
US 11859234
Method of monitoring RNase L activity
granted -
US 11814625
Aptamers as a therapeutic tool to prevent protein aggregation in neurodegenerative disease
granted -
US 11737981
Cellulosic polymer nanoparticles and methods of forming them
granted -
US 11629174
Cryptic metabolites and method for activating silent biosynthetic gene clusters in actinomycete bacteria
granted -
US 11554101
Process for encapsulating soluble biologics, therapeutics, and imaging agents
granted -
US 11549950
Cryptic metabolites and method for activating silent biosynthetic gene clusters in diverse microorganisms
granted -
US 11486802
Methods and devices for high throughput purification
granted -
US 11376225
Composite flash-precipitated nanoparticles
granted -
US 11312756
Engineered potent cytotoxic stapled BH3 peptides
granted -
US 11147784
Dietary supplements and composition for treating cancer
granted -
US 11103461
Process for encapsulating soluble biologics, therapeutics, and imaging agents
granted -
US 11008551
Method to increase the infectivity of virus particles
granted -
US 10980990
Systems, devices, and/or methods for managing transdermal patches
granted -
US 10940119
Nano-encapsulation using GRAS materials and applications thereof
granted -
US 10905775
Particulate constructs for release of active agents
granted -
US 10883980
Methods and compositions for inhibiting hepatitis E virus
granted -
US 10852220
Methods and devices for high throughput purification
granted -
US 10842980
Systems, devices, and/or methods for managing transdermal patches
granted
Frequently asked questions
What is nitisinone?
nitisinone (NITYR) is a 4-hydroxyphenylpyruvate dioxygenase inhibitor. Associated with Eton Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for nitisinone?
NITYR is a marketed brand name for nitisinone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of nitisinone?
nitisinone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.